ABCD updates FIP treatment guidance as antivirals reshape care: full analysis

The latest ABCD FIP treatment update marks another step in one of small animal medicine’s fastest-moving clinical turnarounds: a disease once associated with euthanasia is now being managed as a condition that can often be treated successfully. Published in Viruses in 2026, the revised guidance says antiviral therapy, particularly oral GS-441524, has fundamentally changed the prognosis for cats with feline infectious peritonitis, and it expands recommendations on drug options, monitoring, and treatment strategy. (eprints.gla.ac.uk)

That shift has been building for several years. Earlier FIP guidance focused heavily on diagnosis, pathogenesis, and supportive care, but the therapeutic landscape changed as published studies accumulated around GS-441524, remdesivir, and, later, molnupiravir and EIDD-1931. The new ABCD document incorporates those newer data and reflects a broader international reality: access to treatment is still uneven, legal pathways differ by market, and clinicians are increasingly balancing efficacy, tolerability, cost, and sourcing. In the U.S., for example, FDA said in May 2024 that it did not intend to enforce new animal drug approval requirements for compounded GS-441524 prescribed by veterinarians for specific feline patients under the conditions in Guidance for Industry #256, while also stressing that the drug is not FDA approved. (eprints.gla.ac.uk)

The guideline’s practical message is clear. Oral GS-441524 is now generally favored to avoid the pain and compliance problems associated with injectable remdesivir, unless remdesivir is the only available antiviral or the cat is too ill to take oral medication. The document also reinforces that ocular and neurologic FIP often require higher dosing, and that treatment duration remains in flux. While 84 days is still the most established course in many protocols, the guideline cites a prospective randomized controlled study showing that a 6-week, or 42-day, oral GS-441524 course was as effective as 84 days in cats with effusive FIP. It also notes that treatment can be extended or doses increased if clinical signs and clinicopathologic abnormalities don't normalize. (abcdcatsvets.org)

The evidence base behind those updates is still expanding. A randomized, double-blind non-inferiority trial published in 2026 compared oral remdesivir with GS-441524 as first-line therapy for non-effusive FIP, underscoring the field’s push toward head-to-head data rather than anecdotal protocol sharing. The ABCD guideline also references 2025 and 2026 studies on oral remdesivir, shorter-course GS-441524 treatment, treatment monitoring, and relapse management, suggesting that FIP care is entering a more evidence-driven phase even as some recommendations still rely on clinician experience and personal communications. (journals.sagepub.com)

Outside the guideline itself, stewardship concerns are getting louder. University of Guelph infectious disease specialist Scott Weese warned in a 2025 commentary that widespread antiviral use for enteric feline coronavirus, where clinical benefit is limited, could create resistance pressure against drugs that are "currently saving countless feline lives." His point aligns with the ABCD update’s broader caution that these therapies should be used thoughtfully, especially as access improves and pressure grows to use them beyond clear FIP cases. The guideline also flags adverse-effect and quality concerns, including transient ALT increases, neutropenia with some alternatives, and rare reports of GS-441524 uroliths that appeared linked to unregulated products. (wormsandgermsblog.com)

Why it matters: For veterinarians, this update is less about declaring victory over FIP than about managing a new standard of care responsibly. The biggest clinical takeaway is that treatment decisions are becoming more nuanced: drug choice may depend on disease form, oral tolerance, legal availability, product quality, and the need for higher CNS or ocular penetration. The biggest operational takeaway is that shorter-course evidence, if confirmed across broader populations, could reduce financial strain and improve adherence for pet parents, while legal compounding pathways may gradually pull treatment away from gray-market sourcing. But that also raises expectations for better monitoring, cleaner communication about prognosis, and stronger antimicrobial-style stewardship around antiviral use. (abcdcatsvets.org)

What to watch: The next inflection points are likely to be validation of shortened protocols beyond effusive FIP, more comparative data on oral remdesivir and rescue therapies, and continued regulatory clarification around legally sourced products in different markets. If those pieces fall into place, FIP management may look less like an exception case and more like a routine, protocolized part of feline practice. (journals.sagepub.com)